NASDAQ: $VTRS
As we approach the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting in Washington, D.C., the medical community is turning its attention toward significant advancements in reproductive health. Viatris Inc. recently announced it will present six new abstracts regarding its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch, marking a milestone in the development of non-invasive, reversible birth control options.
The Future of Transdermal Contraception
The upcoming presentations, scheduled for May 1-3, 2026, provide a comprehensive look at the investigational patch, referred to as MR-100A-01. The data stems from a robust Phase 3 study (NCT05139121) and offers clinicians insights into efficacy, safety, and patient experience. For many women of childbearing potential—particularly those with a BMI below 30 kg/m²—the ability to access a lower estrogen dose in a convenient, once-weekly format represents a significant shift in contraceptive care.
Key Scientific Highlights
The Viatris program at ACOG covers critical areas of clinical performance. Notably, researchers will present findings on:
- Efficacy and Safety: Comprehensive results from the Phase 3 trial assessing the contraceptive reliability of the weekly system.
- Adhesion Performance: Perhaps one of the most practical concerns for patients using transdermal systems, new data will showcase the patch’s adhesion profile under both normal and extreme conditions.
- Pharmacokinetics and Cycle Control: Comparative data between the weekly patch and daily oral contraceptives, as well as an analysis of cycle control, provide the necessary evidence for clinicians to weigh this option against existing methods.
The electronic posters will be presented throughout the day on Saturday, May 2, allowing for peer-to-peer engagement and discussion on how these findings may be integrated into clinical practice.
Educational Support for Clinicians
Beyond the primary data presentations, Viatris is supporting the broader educational landscape of reproductive health. The company has provided an independent educational grant for a symposium titled, “Contraceptive Considerations in the Modern Era: Navigating Non-Oral Options and Evolving Clinical Complexities.” This session, held on May 1, aims to assist providers in staying updated on the shifting preferences for non-oral hormonal contraception.
What Comes Next?
The investigational patch is currently under review by the U.S. Food and Drug Administration (FDA) via the 505(b)(2) regulatory pathway. With a target action date of July 30, 2026, the medical community is closely monitoring this potential addition to the contraceptive market. By building on its existing experience with transdermal drug delivery, Viatris aims to provide a solution that balances high efficacy with the convenience of a lower-estrogen, once-weekly application.
For those attending the ACOG 2026 meeting, Viatris will be available at booth #223 to answer questions and provide further context on these developments. All scientific abstracts are available for review on the official ACOG Annual Meeting website.